<DOC>
	<DOCNO>NCT00669422</DOCNO>
	<brief_summary>This study collect patient demographic , oncology history , physician report outcome information follow initial round chemotherapy receive commercial ChemoFx® Final Report generation hypotheses potential patient cohort sub-studies .</brief_summary>
	<brief_title>ChemoFx® PRO - A Post-Market Data Collection Study</brief_title>
	<detailed_description>The traditional treatment course new case many cancer cytoreductive surgery follow chemotherapy . Unfortunately , despite high initial response rate treatment , majority patient recur . The use ineffective chemotherapy result unnecessary toxicity cost , delay effective treatment , potential development cross-resistance additional drug . The ability individualize therapy provide treat physician ex vivo response information panel drug aid selection effective therapy individual patient , thus result improve outcome . ChemoFx® drug response marker quantifies individual cancer patient 's probable tumor response various chemotherapeutic biologic agents—providing sensitivity resistance information . In retrospective study , demonstrate patient treated regimen ChemoFx® test say patient ' cell would sensitive , correspond 3 time long progression free interval . In PT-206 ChemoFx PRO® study , patient follow treatment , patient progress significant change chemotherapy occur . This data collect analyzed identify potential patient cohort development hypotheses future sub-study analysis . Also , tumor pathology slide excess tumor cell ( available ) use characterize common polymorphisms drug metabolizing enzymes well molecular marker potentially associate tumor response . The PT-206 ChemoFx PRO® Study seek enroll estimate 3,000 patient 150 academic community-based physician U.S . The patient treat drug and/or drug combination base medical judgment treat physician . This study randomize .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Endometrial Neoplasms</mesh_term>
	<mesh_term>Vulvar Neoplasms</mesh_term>
	<mesh_term>Vaginal Neoplasms</mesh_term>
	<mesh_term>Uterine Neoplasms</mesh_term>
	<criteria>Patient diagnose solid tumor malignancy physician receive final report ChemoFx® August 1 , 2006 Chemotherapy must clinically indicate treatment patient 's qualifying disease Patient must least 18 year age Patient must sign IRB approve informed consent form data collection study prior entry data enrollment form database . Patient pathology show benign pathology sample submit Patient indicate receive chemotherapy disease</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Ovarian Cancer</keyword>
	<keyword>Fallopian Tube Cancer</keyword>
	<keyword>Peritoneal Cancer</keyword>
	<keyword>Uterine Neoplasms</keyword>
	<keyword>Vulvar Cancer</keyword>
	<keyword>Endometrial Cancer</keyword>
	<keyword>Cervical Cancer</keyword>
	<keyword>Assay</keyword>
	<keyword>Chemotherapy</keyword>
	<keyword>Recurrent</keyword>
	<keyword>Refractory</keyword>
	<keyword>Persistent</keyword>
	<keyword>Chemoresponse</keyword>
	<keyword>Sensitivity</keyword>
	<keyword>Precision Therapeutics</keyword>
	<keyword>ChemoFx</keyword>
</DOC>